Caris Life Sciences Aktie News

Caris Life Sciences, Inc. ( CAI ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants J. Denton - Senior VP, General Counsel & Secretary David Halbert - Chairman, CEO & Founder Brian Brille - Executive Vice Chairman & Executive VP David Spetzler - President Luke Power - Senior VP, CFO & Chief Accounting Officer Conference Call Participants Vijay Kumar - Evercore ISI Institut...

Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million, representing year-over-year growth of 75-77% IRVING, Texas , Nov. 5, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended September...

IRVING, Texas , Oct. 29, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced collaborative new research identifying TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors. The study titled...

IRVING, Texas , Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m.

IRVING, Texas , Oct. 14, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, will unveil six studies at the European Society for Medical Oncology (ESMO) Congress 2025, in Berlin, Germany from October 17-21, 2025. These presentations highlight the transformative power of multiomics, a scientific ...

Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. CAI's revenue growth is robust, driven primarily by molecular profiling, but overdependence on this segment and execution across diverse fronts pose risks. The company boasts industry-leading breadth—tissue and blood testing, early...